FINWIRES · TerminalLIVE
FINWIRES

Gilead Sciences Gets FDA Approval for Hepcludex

By

Gilead Sciences (GILD) has received approval from the US Food and Drug Administration for Hepcludex to treat chronic hepatitis delta virus infection in adults without advanced liver scarring, or with compensated cirrhosis, the FDA said Friday.

The therapy is the first FDA-approved treatment for chronic HDV infection, a serious condition that can cause liver fibrosis, liver cancer, liver failure, and even death, the regulator said.

The efficacy of Hepcludex was shown in a phase 3 trial, it said.

Shares were up over 2% in afternoon trading.

Price: $133.74, Change: $+3.24, Percent Change: +2.48%

Related Articles

Wire

Zoom Communications Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Zoom Communications (ZM) reported fiscal Q1 adjusted diluted earnings late Thursday of $1.55 a share, up from $1.43 a year earlier.Analysts polled by FactSet expected $1.42.Revenue in the three months ended April 30 rose to $1.24 billion from $1.17 billion a year earlier.Analysts surveyed by FactSet expected $1.22 billion.The company expects fiscal Q2 non-GAAP diluted EPS of $1.45 to $1.47 on revenue of $1.265 billion to $1.27 billion. Analysts expect EPS of $1.49 on revenue of $1.266 billion.Zoom expects full-year non-GAAP diluted EPS of $5.96 to $6 on revenue of $5.08 billion to $5.09 billion, up from the prior outlook of EPS of $5.77 to $5.81 on revenue of $5.065 billion to $5.075 billion.Analysts polled by FactSet expect EPS of $5.88 on revenue of $5.075 billion.Zoom shares rose 7% in after-hours trading.

$ZM
Wire

Deckers Outdoor Fiscal Q4 Earnings Fall, Revenue Rises; Sets Fiscal 2027 Guidance

Deckers Outdoor (DECK) reported fiscal Q4 earnings late Thursday of $0.96 per diluted share, down from $1.00 a year earlier.Analysts polled by FactSet expected $0.83.Net sales for the quarter ended March 31 were $1.12 billion, up from $1.02 billion a year earlier.Analysts surveyed by FactSet expected $1.09 billion.The company expects fiscal 2027 earnings of $7.30 to $7.45 per share on net consolidated sales of $5.86 billion to $5.91 billion. Analysts polled by FactSet expect $7.35 and $5.82 billion, respectively.The company said its board has approved an increase of $3.5 billion to the stock repurchase authorization, which brings total outstanding authorization to about $5 billion.

$DECK
Wire

Earnings Flash (TTWO) Take-Two Interactive Software Posts Fiscal Q4 Per Share Loss -$0.32, vs. FactSet Est of $-0.57 Loss

Earnings Flash (TTWO) Take-Two Interactive Software Posts Fiscal Q4 Per Share Loss -$0.32, vs. FactSet Est of $-0.57 Loss

$TTWO